CLAIMS

1. An antibody variable domain, which specifically binds to IL-4R, comprising:
   a) a VH chain having a sequence selected from SEQ ID NOs: 4, 5, 6, 7, 8 and 9, and
   b) a VL chain having a sequence selected from SEQ ID NOs: 14, 15, 16, 17 and 18.

2. The antibody variable domain of claim 1, wherein said antibody variable domain comprises:
   a) a VH chain having the sequence of SEQ ID NO: 4 and a VL chain having the sequence of SEQ ID NO: 14; or
   b) a VH chain having the sequence of SEQ ID NO: 4 and a VL chain having the sequence of SEQ ID NO: 17; or
   c) a VH chain having the sequence of SEQ ID NO: 4 and a VL chain having the sequence of SEQ ID NO: 18; or
   d) a VH chain having the sequence of SEQ ID NO: 5 and a VL chain having the sequence of SEQ ID NO: 15; or
   e) a VH chain having the sequence of SEQ ID NO: 6 and a VL chain having the sequence of SEQ ID NO: 16; or
   f) a VH chain having the sequence of SEQ ID NO: 7 and a VL chain having the sequence of SEQ ID NO: 14; or
   g) a VH chain having the sequence of SEQ ID NO: 8 and a VL chain having the sequence of SEQ ID NO: 18; or
   h) a VH chain having the sequence of SEQ ID NO: 9 and a VL chain having the sequence of SEQ ID NO: 14.

3. The antibody variable domain of claim 1 or 2, wherein said antibody variable domain is selected from a FAB, an Fv, an scFv and a dsFv.

4. The antibody variable domain of claim 3, which is an scFv antibody having a sequence selected from SEQ ID NOs: 33 to 39.

5. A multispecific antibody comprising:
   a) one or two antibody variable domains as defined in any one of claims 1 to 4;
   b) at least one binding domain, which specifically binds to a target different from IL-4R.

6. The multispecific antibody of claim 5, wherein the multispecific antibody does not comprise an immunoglobulin Fc region.

7. The multispecific antibody of claim 6, wherein the multispecific antibody is in a format selected from the group consisting of: a tandem scDb (Tandab), a linear dimeric scDb (LD-scDb), a circular dimeric scDb (CD-scDb), a tandem tri-scFv, a tribody (Fab-$(scFv)_2$), a Fab-Fv_2, atriabody, an scDb-scFv, a tetrabody, a di-diabody, a tandem-di-scFv and a MATCH.

8. The multispecific antibody of claim 5, wherein the multispecific antibody comprises an immunoglobulin Fc region that is selected from IgG subclasses IgG1 and IgG4, particularly from IgG4.

9. The multispecific antibody of claim 8, wherein the format of said multispecific antibody is selected from KiH-based IgGs; DVD-Ig; CODV-IgG and Morrison (IgG CH_3-scFv fusion (Morrison H) or IgG CL-scFv fusion (Morrison L)), in particular from Morrison H and Morrison L.

10. The multispecific antibody of any one of claims 5 to 9, wherein said multispecific antibody comprises two antibody variable domains as defined in any one of claims 1 to 4 and two binding domains, which specifically bind to a second target different from IL-4R.

11. A nucleic acid or two nucleic acids encoding the antibody variable domain of any one of claims 1 to 4 or the multispecific antibody of any one of claims 5 to 10.

12. A vector or two vectors comprising the nucleic acid or the two nucleic acids of claim 11.

13. A host cell or host cells comprising the vector or the two vectors of claim 12.

14. A pharmaceutical composition comprising the antibody variable domain of any one of claims 1 to 4 or the multispecific antibody of any one of claims 5 to 10 and a pharmaceutically acceptable carrier.

15. The antibody variable domain of any one of claims 1 to 4 or the multispecific antibody of any one of claims 5 to 10 for use as a medicament.

16. Use of the antibody variable domain of any one of claims 1 to 4 or the multispecific antibody of any one of claims 5 to 10 in the manufacture of a medicament for treating a disease, particularly a human disease, more particularly a human disease selected from allergic, inflammatory and autoimmune diseases, particularly from inflammatory and autoimmune diseases.